Pregledni rad
18 O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases
Emirhan Nemutlu
; Division of Cardiovascular Diseases, Department of Medicine Mayo Clinic, Rochester, Minn, USA
Song Zhang
; Division of Cardiovascular Diseases, Department of Medicine Mayo Clinic, Rochester, Minn, USA
Nenad O. Juranic
; Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester Minn, USA
Andre Terzic
; Division of Cardiovascular Diseases, Department of Medicine Mayo Clinic, Rochester, Minn, USA
Slobodan Macura
; Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester Minn, USA
Petras Dzeja
; Division of Cardiovascular Diseases, Department of Medicine Mayo Clinic, Rochester, Minn, USA
Sažetak
Technological innovations and translation of basic discoveries
to clinical practice drive advances in medicine.
Today’s innovative technologies enable comprehensive
screening of the genome, transcriptome, proteome, and
metabolome. The detailed knowledge, converged in the
integrated “omics” (genomics, transcriptomics, proteomics,
and metabolomics), holds an immense potential for understanding
mechanism of diseases, facilitating their early
diagnostics, selecting personalized therapeutic strategies,
and assessing their effectiveness. Metabolomics is the
newest “omics” approach aimed to analyze large metabolite
pools. The next generation of metabolomic screening
requires technologies for high throughput and robust
monitoring of metabolite levels and their fluxes. In this regard,
stable isotope 18O-based metabolite tagging technology
expands quantitative measurements of metabolite
levels and turnover rates to all metabolites that include
water as a reactant, most notably phosphometabolites.
The obtained profiles and turnover rates are sensitive indicators
of energy and metabolic imbalances like the ones
created by genetic deficiencies, myocardial ischemia, heart
failure, neurodegenerative disorders, etc. Here we describe
and discuss briefly the potential use of dynamic phosphometabolomic
platform for disease diagnostics currently
under development at Mayo Clinic.
Ključne riječi
Hrčak ID:
94954
URI
Datum izdavanja:
15.12.2012.
Posjeta: 1.210 *